Literature DB >> 21374544

Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus.

P Yan1, D Liu, M Long, Y Ren, J Pang, R Li.   

Abstract

BACKGROUND: Omentin has recently been characterized as a potent insulin-sensitizing adipokine, but its pathophysiologic roles in humans remain largely unknown.
OBJECTIVE: To investigate the change of fasting serum omentin levels and evaluate the relationship of omentin with adiponectin in patients with type 2 diabetes mellitus.
DESIGN: 35 patients with newly diagnosed type 2 diabetes (T2DM), 35 patients with impaired glucose regulation (IGT) and 35 patients with normal glucose tolerance (NGT) participated in this study. Fasting serum omentin and adiponectin levels were measured by enzyme-linked immunosorbent assay. The relationship between serum omentin, serum adiponectin levels and metabolic parameters was also analyzed.
RESULTS: Fasting serum omentin levels were significantly lower in T2DM and IGT groups than in NGT group (16.75±1.71 vs. 18.62±1.22 vs. 24.60±1.43 ng/ml, all P<0.01). Obesity subjects had significantly lower serum omentin levels than normal body weight subjects ( P<0.01 or P<0.05). Female subjects had moderately higher fasting serum omentin levels than male subjects. Fasting serum adiponectin levels showed a similar variation trend to omentin in T2DM and NGT groups, obesity and normal body weight subjects, female and male subjects. Fasting serum omentin levels were negatively correlated with HOMA-IR and positively correlated with adiponectin. Moreover, HOMA-IR and adiponectin were the independently predictors of fasting serum omentin levels.
CONCLUSIONS: Serum omentin levels possibly play an important role in the pathogenesis of insulin resistance and diabetes. More importantly, there is such a close connection between serum omentin and adiponectin levels that regulation of omentin may be dependent on adiponectin. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21374544     DOI: 10.1055/s-0030-1269912

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  30 in total

1.  Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.

Authors:  Grigorios Panagiotou; Lin Mu; Brian Na; Kenneth J Mukamal; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-06-09       Impact factor: 8.694

2.  New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients.

Authors:  Hanaa H Ahmed; Wafaa Gh Shousha; Hatem A El-Mezayen; Ibrahim A Emara; Marwa E Hassan
Journal:  Indian J Clin Biochem       Date:  2018-07-17

3.  Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes.

Authors:  Corinna Niersmann; Maren Carstensen-Kirberg; Haifa Maalmi; Bernd Holleczek; Michael Roden; Hermann Brenner; Christian Herder; Ben Schöttker
Journal:  Diabetologia       Date:  2019-11-09       Impact factor: 10.122

Review 4.  Insights into the Link Between Obesity and Cancer.

Authors:  Sarah E Ackerman; Olivia A Blackburn; François Marchildon; Paul Cohen
Journal:  Curr Obes Rep       Date:  2017-06

5.  Circulating adiponectin mediates the association between omentin gene polymorphism and cardiometabolic health in Asian Indians.

Authors:  Karani Santhanakrishnan Vimaleswaran; Dhanasekaran Bodhini; Juanjie Jiang; Kandaswamy Ramya; Deepa Mohan; Coimbatore Subramanian Shanthi Rani; Nagarajan Lakshmipriya; Vasudevan Sudha; Rajendra Pradeepa; Ranjit Mohan Anjana; Viswanathan Mohan; Venkatesan Radha
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

6.  Association between omentin-1 and indices of glucose metabolism in early pregnancy: a pilot study.

Authors:  Stefania Papatheodorou; Bizu Gelaye; Michelle A Williams
Journal:  Arch Gynecol Obstet       Date:  2021-08-24       Impact factor: 2.344

7.  Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus.

Authors:  Hyun Min Kim; Byung-Wan Lee; Young-Mi Song; Won Jin Kim; Hyuk-Jae Chang; Dong-Hoon Choi; Hee Tae Yu; Eunseok Kang; Bong Soo Cha; Hyun Chul Lee
Journal:  Cardiovasc Diabetol       Date:  2012-07-18       Impact factor: 9.951

8.  Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes.

Authors:  Hye Jin Yoo; Soon Young Hwang; Ho Cheol Hong; Hae Yoon Choi; Sae Jeong Yang; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Kyung Mook Choi; Dong Seop Choi; Sei Hyun Baik
Journal:  Cardiovasc Diabetol       Date:  2011-11-22       Impact factor: 9.951

9.  Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity.

Authors:  Gillian Barker; Ratana Lim; Harry M Georgiou; Martha Lappas
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

10.  Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.

Authors:  Sabrina Greulich; Weena J Y Chen; Bujar Maxhera; Luuk J Rijzewijk; Rutger W van der Meer; Jacqueline T Jonker; Heidi Mueller; Daniella Herzfeld de Wiza; Ralf-Ruediger Floerke; Konstantinos Smiris; Hildo J Lamb; Albert de Roos; Jeroen J Bax; Johannes A Romijn; Jan W A Smit; Payam Akhyari; Artur Lichtenberg; Juergen Eckel; Michaela Diamant; D Margriet Ouwens
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.